Topic: neuropathy

Office lobby

4. Pfizer

For many years, Pfizer was hit by waves of criticism for its failure to develop new blockbusters to replace the big drugs that had bulked up its revenue. Those critics wanted to see more outsourcing, more partnerships and smaller in-house research empires. Pfizer has in many ways steered toward that course, and 2016 saw more evidence of this.

NIH: novel gene may drive progression of rare neuropathy in children

Neuropathy is a condition associated with a progressive decline in motor and sensory function; as such, patients can suffer from a wide range of symptoms, including muscle weakness and pain. National Institutes of Health (NIH) scientists now identify a genetic cause that might reveal itself as a potential drug target for a rare form of neuropathy.